Neurocrine Biosciences (NASDAQ:NBIX) Rating Lowered to “Buy” at Wall Street Zen

Neurocrine Biosciences (NASDAQ:NBIX) was downgraded by stock analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a report released on Monday.

A number of other brokerages have also recently commented on NBIX. Canaccord Genuity Group boosted their price target on Neurocrine Biosciences from $160.00 to $164.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. JPMorgan Chase & Co. cut their target price on Neurocrine Biosciences from $179.00 to $177.00 and set an “overweight” rating on the stock in a research note on Monday, January 12th. Wedbush raised their price target on Neurocrine Biosciences from $149.00 to $151.00 and gave the company an “outperform” rating in a report on Thursday. UBS Group dropped their price target on shares of Neurocrine Biosciences from $188.00 to $178.00 and set a “buy” rating on the stock in a research note on Friday, January 23rd. Finally, Royal Bank Of Canada cut their price objective on shares of Neurocrine Biosciences from $180.00 to $177.00 and set an “outperform” rating on the stock in a research report on Thursday. Sixteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $177.42.

Neurocrine Biosciences Price Performance

NASDAQ:NBIX opened at $124.12 on Monday. The firm’s 50-day moving average price is $140.14 and its 200-day moving average price is $140.46. The company has a market capitalization of $12.46 billion, a PE ratio of 26.64, a P/E/G ratio of 0.57 and a beta of 0.31. Neurocrine Biosciences has a 1-year low of $84.23 and a 1-year high of $160.18.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Wednesday, February 11th. The company reported $1.88 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.36 by ($0.48). The business had revenue of $805.50 million for the quarter, compared to analysts’ expectations of $804.21 million. Neurocrine Biosciences had a net margin of 16.73% and a return on equity of 16.48%. The company’s revenue was up 28.3% on a year-over-year basis. During the same period last year, the business earned $1.69 earnings per share. Equities analysts anticipate that Neurocrine Biosciences will post 4.28 EPS for the current fiscal year.

Insiders Place Their Bets

In other Neurocrine Biosciences news, CEO Kyle Gano sold 36,400 shares of the company’s stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $132.70, for a total transaction of $4,830,280.00. Following the transaction, the chief executive officer owned 140,407 shares in the company, valued at approximately $18,632,008.90. This represents a 20.59% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Darin Lippoldt sold 4,376 shares of Neurocrine Biosciences stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $159.65, for a total transaction of $698,628.40. Following the completion of the sale, the insider owned 43,405 shares of the company’s stock, valued at $6,929,608.25. This represents a 9.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 61,966 shares of company stock valued at $8,625,166 over the last quarter. Corporate insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Neurocrine Biosciences

Hedge funds have recently added to or reduced their stakes in the stock. USA Financial Formulas purchased a new position in shares of Neurocrine Biosciences in the 4th quarter worth $25,000. Geneos Wealth Management Inc. lifted its holdings in Neurocrine Biosciences by 143.6% in the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after acquiring an additional 135 shares during the period. Golden State Wealth Management LLC boosted its position in Neurocrine Biosciences by 120.5% in the third quarter. Golden State Wealth Management LLC now owns 183 shares of the company’s stock worth $26,000 after purchasing an additional 100 shares during the last quarter. Eastern Bank bought a new stake in shares of Neurocrine Biosciences during the 3rd quarter valued at about $27,000. Finally, DJE Kapital AG purchased a new stake in shares of Neurocrine Biosciences during the 4th quarter valued at about $28,000. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Multiple analysts reiterated Buy/Outperform ratings and raised some price targets (Citigroup to $204, Bank of America reiterated Buy with a $190 target, Needham nudged to $185), signaling continued confidence in Ingrezza durability and pipeline upside. Analyst moves (Benzinga / TipRanks)
• Positive Sentiment: Q4 revenue grew strongly (~28% YoY to ~$805.5M) and company commentary highlighted Ingrezza sales growth and emerging uptake of pipeline assets — supports longer-term revenue trajectory. Earnings highlights (Yahoo)
• Neutral Sentiment: Deeper analysis pieces discuss growth beyond Ingrezza and portfolio opportunities that could drive medium-term upside but caution that 2026 may be less eventful. Useful for investors assessing longer-horizon thesis. Seeking Alpha: Growth Beyond Ingrezza
• Neutral Sentiment: Full Q4 earnings call transcripts and analyst note compilations are available for investors wanting primary commentary on guidance, expense cadence, and pipeline timelines. Review for detail before trading on headlines. Earnings transcripts & summaries
• Negative Sentiment: EPS missed expectations (Q4 EPS ~$1.88 vs. several consensus figures higher), and management issued cautious 2026 guidance — the combination sparked downside pressure and short-term uncertainty. Zacks: Q4 EPS lag
• Negative Sentiment: Some firms trimmed price targets or downgraded to Market Perform (BMO to $140; RBC and Wells Fargo trimmed targets though keeping Outperform/Overweight designations), reflecting more cautious near-term outlooks. Price target changes (Benzinga)
• Negative Sentiment: Market commentary highlights the stock’s sharp pullback after guidance and the EPS miss — articles explaining recent 8%+ decline underscore the sentiment risk if sales or cost pressures persist. AAII: Why NBIX is down

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.